ROS-Activated Prodrugs for Selective Anti-Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-cancer therapeutic drugs often suffer from non-selectivity, leading to high toxicity in normal cells and limited efficacy due to their interaction with proliferating cells, including DNA modification, resulting in intolerable side effects and reduced effectiveness in treating ROS-associated cancers like leukemia.
Innovation Solution
Development of novel anti-cancer compounds that are activated by reactive oxygen species (ROS), specifically hydrogen peroxide, which convert into cytotoxic DNA-modifying agents within cancer cells, minimizing off-target effects on normal cells by leveraging elevated ROS levels in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-cancer drugs are used to treat cancer cells, then cytotoxic efficacy is achieved, but selectivity is lost leading to high toxicity in normal cells
Solution Approach 1:
The patent applies preliminary action by designing a prodrug that is administered in its inactive form and only activated within cancer cells. The compound 2-(cyclohexylamino)-N-(2,5-dihydroxyphenyl)acetamide is given as a prodrug that requires intracellular activation by cancer cell-specific enzymes or conditions, ensuring that the cytotoxic action occurs only after the drug has been taken up by target cells, thereby protecting normal cells from exposure to the active toxic agent
Solution Approach 2:
The patent uses an intermediary mechanism by introducing a bioorthogonal functional group or enzyme-specific substrate as a mediator between the prodrug and its activation. This intermediary allows selective conversion of the inactive prodrug to its active cytotoxic form only in the presence of cancer cell-specific enzymes or biochemical conditions, creating a bridge that enables selective activation while protecting normal tissues from direct exposure to the toxic agent
2Productivity
If DNA-modifying agents are used to treat proliferating cancer cells, then anti-cancer efficacy is improved, but off-target effects on normal replicating cells increase
Solution Approach 1:
The patent applies local quality by designing a compound with distinct functional regions: a bioorthogonal functional group or enzyme-specific substrate that provides selective localization to cancer cells, and a cytotoxic warhead that remains inactive until localized. This spatial separation of recognition and toxic functions ensures that DNA modification occurs only in cancer cells where the bioorthogonal group or enzyme substrate binds selectively, preventing off-target effects on normal replicating cells
Solution Approach 2:
The patent uses preliminary action by administering the DNA-modifying agent in an inactive prodrug form that cannot interact with DNA until activated. The bioorthogonal functional group or enzyme-specific substrate enables preliminary selective uptake and accumulation in cancer cells before activation, ensuring that DNA modification occurs only after the compound has been selectively concentrated in target cells, thereby avoiding off-target effects on normal cells
3Reliability
If high doses of chemotherapy drugs are administered to overcome resistance, then treatment efficacy increases, but side effects become intolerable
Solution Approach 1:
The patent converts harm into benefit by utilizing the unique biochemical environment of cancer cells (such as elevated ROS levels, specific enzyme expression, or metabolic characteristics) as the activating condition for the prodrug. The harmful cytotoxic agent is transformed into a beneficial selective therapy because the cancer cell's own biochemical properties become the trigger for activation, turning what would normally be a source of toxicity into a mechanism for selective targeting and reducing side effects while maintaining efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ROS-activated compounds demonstrate enhanced selectivity and efficacy in targeting cancer cells, particularly those with elevated ROS levels, such as acute myeloid leukemia, while maintaining low toxicity to normal cells, thereby improving treatment outcomes for ROS-associated cancers.
Implementation Method 1
compounds that are activated by and specifically target cancer cells associated with elevated levels of reactive oxygen species (ROS), particularly hydrogen peroxide
Data Source
Figure 1
Figure 2
Figure 3A~3E
AI summary
Provided are compounds according to the following Formula I: The Formula I compounds are activated in the presence of hydrogen peroxide and are therefore selective anti-cancer therapeutics for cancers associated with elevated reactive oxygen species (ROS). Also provided are methods and pharmaceutical compositions for treating cancers associated with increased ROS.